Soterios Limited

Soterios Limited is a United Kingdom-based pharmaceutical company focused on dermatology. According to its official website, the company is dedicated to "developing and commercialising medicines for dermatology diseases with major unmet needs," and it describes a strategy that leverages deep scientific knowledge of medical dermatology to identify "de-risked" opportunities to improve patients' lives. The company is headquartered in Salisbury, United Kingdom, according to its Wikidata entry. Soterios's lead programme is STS-01, a non-steroidal topical therapy being developed for mild-to-moderate (patchy) alopecia areata. Alopecia areata is a chronic immune-mediated disorder characterised by non-scarring hair loss on the scalp and body. The company highlights that this is a major under-served area of dermatology, particularly for patients with mild-to-moderate disease, for whom there are no approved therapies despite a disease burden comparable to severe cases. Soterios cites approximately 800,000 patients in the United States, of whom at least 50% are mild-to-moderate "patchy" alopecia areata sufferers, and notes that the FDA recognises alopecia areata as a debilitating condition and a priority for new therapies across all severities. STS-01 is designed to address the need for an effective, safe and convenient non-steroidal topical therapy. It builds on a mechanism with a well-established safety profile in dermatology and existing evidence of efficacy in this indication through targeting key relevant cytokines. Soterios states that STS-01 has been modified to maximise the efficacy of this mechanism and to offer a cosmetically elegant topical cream. The company contrasts its approach with JAK inhibitors, which it says have the potential to offer a new treatment option for severe patients but whose broader use will be limited by concerns with their side effect profiles and price. Soterios has announced positive topline data from a 158-patient Phase II study of STS-01. The company's management team includes David Fleet as Chief Executive Officer, Mark Brimble as Chief Business Officer, and Josh Fleet as Chief Operating Officer. David Fleet is described as having over 35 years of experience. Soterios operates as a private company and is not known to be listed on any public stock exchange. Its activities span the United Kingdom and the United States, reflecting the international scope of its clinical development and commercial ambitions in dermatology.

Soterios Limited is a United Kingdom-based pharmaceutical company focused on dermatology. Its official website states that the company is engaged in "developing and commercialising medicines for dermatology diseases with major unmet needs." The company is headquartered in Salisbury, United Kingdom, according to its Wikidata entry. The exact founding date and founders are not specified in the available evidence. Soterios's strategy is described as leveraging deep scientific knowledge of medical dermatology to identify "de-risked" opportunities to improve patients' lives. Its lead programme, STS-01, is a non-steroidal topical therapy being developed for mild-to-moderate (patchy) alopecia areata. Alopecia areata is a chronic immune-mediated disorder characterised by non-scarring hair loss on the scalp and body. The company notes that this represents a major under-served area of dermatology, particularly for patients with mild-to-moderate disease, for whom there are no approved therapies despite a disease burden as significant as that of severe disease. Soterios cites approximately 800,000 patients in the United States, of whom at least 50% are mild-to-moderate "patchy" alopecia areata sufferers, and notes that the FDA recognises alopecia areata as a debilitating condition and a priority for new therapies across all severities. STS-01 is designed to address the need for an effective, safe and convenient non-steroidal topical therapy. It builds on a mechanism with a well-established safety profile in dermatology and existing evidence of efficacy in this indication through targeting key relevant cytokines. Soterios states that STS-01 has been modified to maximise the efficacy of this mechanism and to offer a cosmetically elegant topical cream. The company contrasts its approach with JAK inhibitors, which it says have the potential to offer a new treatment option for severe patients but whose broader use will be limited by concerns with their side effect profiles and price. Soterios has announced positive topline data from a 158-patient Phase II study of STS-01. The company's management team includes David Fleet as Chief Executive Officer, Mark Brimble as Chief Business Officer, and Josh Fleet as Chief Operating Officer. David Fleet is described as having over 35 years of experience. Soterios operates as a private company and is not known to be listed on any public stock exchange. Its activities span the United Kingdom and the United States, reflecting the international scope of its clinical development and commercial ambitions in dermatology.

• Soterios Limited is established as a dermatology-focused pharmaceutical company in Salisbury, United Kingdom.

• STS-01 completes Phase II trial for mild-to-moderate alopecia areata, with positive topline data announced from a 158-patient study.

Dermatology-focused pharmaceutical company developing de-risked, non-steroidal topical therapies for major unmet needs, with an initial focus on mild-to-moderate alopecia areata.

• STS-01

  A non-steroidal topical cream in development for mild-to-moderate (patchy) alopecia areata. It targets key relevant cytokines and builds on a mechanism with a well-established safety profile in dermatology. Positive topline data from a 158-patient Phase II study have been announced.

1. 1Soterios Pharma – Innovation in Dermatologysoteriospharma.com
2. 2Soterios Limited (United Kingdom) - Wikidatawikidata.org